Table 1 Main characteristics of the studies included in the meta-analysis
Author | Year | Country | Cancer | Sample | Method | patients number | OS | DFS | Follow up (months) | Data extraction method | NOS | Ref | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
high expression | low expression | total | HR (95% CL) | P | HR (95% CL) | P | ||||||||||
Li | 2017 | China | hepatocellular carcinoma | tissue | qRT-PCR | 42 | 42 | 84 | 2.25(1.14–4.43) | 0.019 | NM | NM | 25 | reported | 8 | [8] |
Chen | 2018 | China | osteosarcoma | tissue | qRT-PCR | 66 | 66 | 132 | 1.90(1.15–3.13) | 0.012 | NM | NM | 72 | reported | 8 | [27] |
Ding | 2018 | China | gastric cancer | tissue | qRT-PCR | 38 | 34 | 72 | 1.19(0.47–3.03) | 0.710 | NM | NM | 60 | K-M | 7 | [11] |
Li | 2018 | China | ovarian cancer | tissue | qRT-PCR | 36 | 26 | 62 | 2.16(1.05–4.46) | 0.036 | NM | NM | 60 | K-M | 7 | [28] |
Liu | 2018 | China | ccRCC | tissue | qRT-PCR | 24 | 16 | 40 | 1.00(0.10–9.97) | 0.999 | 1.20(0.21–6.81) | 0.840 | 50 | K-M | 6 | [15] |
Peng | 2018 | China | gastric cancer | tissue | qRT-PCR | 27 | 31 | 58 | 2.49(1.06–5.83) | 0.036 | NM | NM | 60 | K-M | 7 | [12] |
Tuo | 2018 | China | bladder cancer | tissue | qRT-PCR | 64 | 64 | 128 | 0.79(0.24–2.63) | 0.706 | 0.83(0.37–1.84) | 0.639 | 60 | K-M | 7 | [16] |
Wang | 2018 | china | ovarian cancer | tissue | qRT-PCR | 30 | 30 | 60 | NM | NM | NM | NM | NM | NM | 6 | [17] |
Wang | 2018 | China | gastric cancer | tissue | qRT-PCR | 30 | 34 | 64 | 1.82(1.09–3.04) | 0.022 | 2.14(1.26–3.63) | 0.005 | 70 | K-M | 7 | [13] |
Yang | 2018 | China | osteosarcoma | tissue | qRT-PCR | 23 | 23 | 46 | 1.92(0.71–5.18) | 0.199 | NM | NM | 50 | K-M | 6 | [10] |
Yao | 2018 | China | breast cancer | tissue | qRT-PCR | 18 | 18 | 36 | 3.34(1.03–10.82) | 0.045 | NM | NM | 50 | reported | 8 | [18] |
Yao | 2018 | China | cholangiocarcinoma | tissue | qRT-PCR | 41 | 34 | 75 | NM | NM | NM | NM | NM | NM | 6 | [29] |
Zhang | 2018 | China | NSCLC | tissue | qRT-PCR | 22 | 23 | 45 | 1.76(0.65–4.74) | 0.267 | NM | NM | 60 | K-M | 6 | [21] |
Zhang | 2018 | China | brain glioma | tissue | qRT-PCR | 24 | 23 | 47 | 2.46(1.13–5.35) | 0.023 | NM | NM | 40 | reported | 8 | [24] |
Zhang | 2018 | China | gastric cancer | tissue | qRT-PCR | 41 | 35 | 76 | 1.42(0.72–2.81) | 0.310 | NM | NM | 60 | K-M | 6 | [14] |
Zou | 2018 | China | breast cancer | tissue | qRT-PCR | 43 | 43 | 86 | NM | NM | NM | NM | NM | NM | 6 | [19] |
Cui | 2019 | China | pancreatic cancer | tissue | qRT-PCR | 45 | 32 | 77 | 2.14(1.18–3.87) | 0.012 | NM | NM | 50 | K-M | 7 | [25] |
Jia | 2019 | China | colorectal cancer | tissue | qRT-PCR | 30 | 31 | 61 | NM | NM | NM | NM | NM | NM | 8 | [26] |
Liu | 2019 | China | lung adenocarcinoma | tissue | qRT-PCR | 37 | 43 | 80 | 1.60(0.45–5.71) | 0.467 | NM | NM | 60 | K-M | 6 | [23] |
Ma | 2019 | China | hepatocellular carcinoma | tissue | qRT-PCR | 30 | 30 | 60 | NM | NM | NM | NM | NM | NM | 6 | [9] |
Zhang | 2019 | China | cervical cancer | tissue | qRT-PCR | NM | NM | 56 | 2.37(0.75–7.50) | 0.142 | NM | NM | 60 | K-M | 7 | [20] |
Zhu | 2019 | China | NSCLC | tissue | qRT-PCR | 33 | 39 | 72 | 0.88(0.28–2.76) | 0.825 | NM | NM | 60 | K-M | 8 | [22] |
Li | 2019 | China | colorectal cancer | tissue | qRT-PCR | 33 | 37 | 70 | 1.31(0.59–2.92) | 0.510 | NM | NM | 60 | K-M | 7 | [32] |
Liu | 2020 | China | gastric cancer | tissue | qRT-PCR | 34 | 34 | 68 | NM | NM | NM | NM | NM | NM | 6 | [30] |
Liu | 2020 | China | breast cancer | tissue | qRT-PCR | 25 | 20 | 45 | NM | NM | NM | NM | NM | NM | 6 | [31] |
Wang | 2020 | China | retinoblastoma | tissue | qRT-PCR | 37 | 33 | 70 | 2.72(0.85–8.68) | 0.090 | NM | NM | 60 | K-M | 7 | [33] |